Pricing Log in Create free account
Saturday 17 October 2026 Export PGNY’s income statement to Excel — free account

Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

26.86 0.60 −2.18%
Market cap
$2.1B
P/E
27.7×
Fwd P/E
19.9×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.93
Total sells 2.25
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — — — — — — —
Sell 2 3 — — 2 — 4 5 1 — 2 —
Insider Ownership 4.64%

Capital & Financial Ratios $m

Market Cap 2,110.00
Revenue 1,310.76
Net Income 78.63
Free Cash Flow 178.38
Net Debt (236.92)
Current Ratio 2.14 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 27.69
Fwd P/E 19.90
P/S ratio 1.60
P/B ratio 4.63
Past 5Y EPS Growth 6.70%
This Y EPS Growth 97.85% (at or above 15%: strong)
Next Y EPS Growth 18.35% (at or above 15%: strong)
Next Y revenue growth 6.70%
Next 5Y EPS Growth 37.70% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of 3.1×; over the ten years it ranged from 0.6× in 2019 to 14.2× in 2021.
P/E against its own 10 years 10.01%
10-year low 10-year high
P/S against its own 10 years 20.99%
10-year low 10-year high
P/B against its own 10 years 27.40%
10-year low 10-year high
EV/Sales against its own 10 years 23.67%
10-year low 10-year high
EV/FCF against its own 10 years 27.32%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 371 228 310 237
Receivables 242 235 220 257
Inventory — — — —
Other — — — —
640 473 552 513
2023 2024 2025 Q'26
Payables 125 95 124 152
ST’ Debt — — — —
Other — — — —
186 169 202 240

Compound Annual Growth %

10y 5y 3y
Sales — 30.17% 17.87%
Cash Flow — 42.16% 37.76%
Earnings — 4.72% 24.45%
Book Value — 25.32% 11.04%

Revenue $m

Mar Jun Sep Dec Year
’26 329 351 — — —
’25 324 333 313 318 1,289
’24 278 304 287 298 1,167
’23 258 279 281 270 1,089
’22 172 195 205 214 787
’21 122 129 122 128 501
’20 81 65 99 100 345
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 46 50 — — —
’25 50 56 51 54 210
’24 26 57 45 52 179
’23 21 76 54 38 189
’22 (11) 19 21 52 80
’21 1 (7) 24 9 26
’20 12 2 15 7 36
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 40 44 — — —
’25 47 50 46 49 192
’24 25 56 43 50 174
’23 20 75 53 37 185
’22 (12) 19 20 51 77
’21 0 (8) 23 8 24
’20 11 2 15 6 35
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.29 0.34 — — —
’25 0.17 0.19 0.15 0.14 0.65
’24 0.17 0.17 0.11 0.12 0.57
’23 0.18 0.15 0.16 0.13 0.62
’22 0.05 0.09 0.13 0.03 0.30
’21 0.15 0.19 0.17 0.15 0.66
’20 0.04 (0.01) 0.05 0.39 0.47
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 13.29 15.59 38.61 25.67 28.03 13.39 17.01

Analyst estimates 2026–2028

Powerpack
High — — — 32.00 44.22 68.32 53.10 44.95 42.08 27.76
People
People Employees — — 163 167 210 313 400 566 680 856
Revenue/emp, $m — 0.00 0.65 1.38 1.64 1.60 1.97 1.92 1.72 1.51
Income, $m
Income, $m Revenue — 49 105 230 345 501 787 1,089 1,167 1,289
Gross margin, % — 15.23 18.44 19.81 20.32 22.40 21.26 21.94 21.71 23.63
EBT — (12) (7) (9) 9 32 24 71 83 95
EBT margin, % — (25.64) (6.54) (3.73) 2.52 6.48 3.11 6.49 7.13 7.41
Net income — (12) 1 (9) 46 66 30 62 54 59
Depreciation — 2 2 2 2 1 2 2 3 5
Per share, $
Per share, $ Revenue — 8.56 19.03 11.08 4.02 5.62 8.54 11.46 12.76 15.05
Earnings — (2.19) 0.12 (0.41) 0.54 0.74 0.33 0.65 0.59 0.68
Cash flow — (1.67) 0.41 (0.07) 0.42 0.29 0.87 1.99 1.96 2.45
Capex — (0.11) (0.10) (0.14) (0.01) (0.02) (0.04) (0.04) (0.06) (0.21)
Free cash flow — (1.78) 0.31 (0.22) 0.41 0.27 0.84 1.95 1.90 2.24
Book value — (17.19) (17.17) 5.51 1.95 2.83 4.09 5.82 4.61 6.02
Shares, m — 6 6 21 86 89 92 95 91 86
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 77.42 68.04 92.70 56.38 28.75 37.22
P/S — 0.62 0.62 2.48 10.54 8.96 3.58 3.25 1.35 1.71
P/B — 0.00 0.00 4.98 21.77 17.82 7.48 6.39 3.74 4.26
EV/Sales — 0.60 0.60 2.15 10.23 8.73 3.35 2.91 1.16 1.47
EV/FCF — 16.15 16.15 (109.92) 100.36 182.86 34.16 17.12 7.80 9.88
Cash, $m
Cash, $m Operating cash flow — (9) 2 (2) 36 26 80 189 179 210
Capex — (1) (1) (3) (1) (2) (3) (4) (5) (18)
Free cash flow — (10) 2 (4) 35 24 77 185 174 192
Balance, $m
Balance, $m Working capital — (1) (6) 96 112 160 274 454 304 349
Total debt — 5 0 — 8 9 8 — — —
Net debt — 0 0 (80) (109) (119) (189) (371) (228) (310)
Shareholders’ equity — (98) (95) 114 167 252 377 553 422 516
Returns, %
Returns, % ROA — (35.31) 1.73 (8.94) 22.98 21.49 6.74 9.55 7.97 8.67
ROIC — 0.00 0.00 17.85 9.05 15.27 7.77 21.31 21.72 25.88
ROE — 13.98 (0.69) (89.47) 33.04 31.41 9.66 13.34 11.14 12.48
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Progyny, Inc. vs peers in Healthcare Plans (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ELV Elevance Health, Inc. $92.9B 19.0× 20.3× +1.40% (above 0%: growing) −13.08% (below 0%: shrinking) −9.01% (below 0%: shrinking) 15.77% 4.56% Compare
CI Cigna Group $79.0B 12.5× 11.4× +6.68% (above 0%: growing) +10.16% (above 0%: growing) +66.93% (above 0%: growing) 88.24% 3.73% Compare
HUM Humana Inc. $51.9B 38.8× 42.9× +26.18% (above 0%: growing) +27.88% (above 0%: growing) +58.51% (above 0%: growing) 13.45% 3.33% Compare
CNC Centene Corporation $34.8B — (loss-making) 24.8× +9.92% (above 0%: growing) n/m +116.61% (above 0%: growing) 8.59% 2.24% Compare
MOH Molina Healthcare, Inc $11.1B — (loss-making) 55.0× −4.84% (below 0%: shrinking) −74.95% (below 0%: shrinking) +5.81% (above 0%: growing) 13.19% 1.33% Compare
OSCR Oscar Health, Inc. $10.3B 18.6× 29.7× +70.40% (above 0%: growing) n/m +316.29% (above 0%: growing) 22.25% 7.96% Compare
CLOV Clover Health Investments, Corp. $2.5B — (loss-making) 292× +55.60% (above 0%: growing) n/m +406.43% (above 0%: growing) 20.59% 3.77% Compare
PGNY Progyny, Inc. $2.1B 27.7× 19.9× +5.30% (above 0%: growing) +80.00% (above 0%: growing) −12.01% (below 0%: shrinking) 25.48% 11.41%
ALHC Alignment Healthcare, Inc. $1.7B 39.4× 80.3× +31.55% (above 0%: growing) +125.00% (above 0%: growing) −229.51% (below 0%: shrinking) 13.55% 3.15% Compare
Median of peers $23.0B 19.0× 36.3× +18.05% +10.16% +62.72% 14.66% 3.53%

All 12 Healthcare Plans stocks →

Progyny, Inc. (PGNY) key facts

  • Strength: Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024.
  • Progyny, Inc. (PGNY) is a Healthcare Plans company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PGNY traded at $26.86, a market capitalization of $2.1 billion.
  • Return on equity was 12.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 8.89 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Progyny, Inc. (PGNY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PGNY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com